Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of multiple sclerosis.

Conclusions Using the matching-adjusted indirect comparison approach, the efficacy of DMF and fingolimod were similar on all clinical outcomes, while patient-reported outcomes showed greater benefit with DMF. Study limitations include possible confounding from unobserved/unknown differences between trials, and trial length may have been insufficient to detect significant differences on disability progression. PMID: 27733070 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/27733070?dopt=Abstract

Source: Current Medical Research and Opinion - October 14, 2016 Category: Research Tags: Curr Med Res Opin Source Type: research

More News: Research